GALECTIN THERAPEUTICS INC. Proceeds from Lines of Credit
GALECTIN THERAPEUTICS INC. (GALT) reported Proceeds from Lines of Credit of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2026-08-14
- GALECTIN THERAPEUTICS INC. proceeds from lines of credit for the quarter ending 2026-06-30 was -$257.00K, a 102.34% decline year-over-year.
- GALECTIN THERAPEUTICS INC. proceeds from lines of credit for the quarter ending 2026-03-31 was $257.00K.
- GALECTIN THERAPEUTICS INC. proceeds from lines of credit for the quarter ending 2025-12-31 was $10.00M.
- GALECTIN THERAPEUTICS INC. proceeds from lines of credit for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- GALECTIN THERAPEUTICS INC. proceeds from lines of credit for fiscal 2025 was $21.00M, a 30.00% decline from fiscal 2024.
- GALECTIN THERAPEUTICS INC. proceeds from lines of credit for fiscal 2024 was $30.00M, a 0.00% change from fiscal 2023.
- GALECTIN THERAPEUTICS INC. proceeds from lines of credit for fiscal 2023 was $30.00M, a 200.00% increase from fiscal 2022.
- GALECTIN THERAPEUTICS INC. proceeds from lines of credit for fiscal 2022 was $10.00M.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$257.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | $10.00M derived: sum of 3 quarters · filed 2026-08-14 | $10.00M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $257.00K 10-Q · filed 2026-05-15 | $10.26M derived: sum of 2 quarters · filed 2026-05-15 | $10.26M derived: sum of 3 quarters · filed 2026-05-15 | $21.26M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $10.00M derived: sum of 2 quarters · filed 2026-03-31 | $21.00M derived: sum of 3 quarters · filed 2026-08-14 | $21.00M 10-K · filed 2026-03-31 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $11.00M derived: sum of 2 quarters · filed 2026-08-14 | $11.00M 10-Q · filed 2025-11-14 | $11.00M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $11.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $11.00M 10-Q · filed 2026-08-14 | $11.00M derived: sum of 3 quarters · filed 2026-08-14 | $21.00M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-05-15 | $10.00M derived: sum of 3 quarters · filed 2026-05-15 | $20.00M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $10.00M derived: sum of 2 quarters · filed 2026-03-31 | $20.00M derived: sum of 3 quarters · filed 2026-03-31 | $30.00M 10-K · filed 2026-03-31 |
| 2024-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $20.00M derived: sum of 2 quarters · filed 2025-11-14 | $30.00M 10-Q · filed 2025-11-14 | $40.00M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $20.00M 10-Q · filed 2025-08-14 | $30.00M derived: sum of 3 quarters · filed 2025-08-14 | $30.00M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $10.00M 10-Q · filed 2025-05-15 | $20.00M derived: sum of 2 quarters · filed 2025-05-15 | $20.00M derived: sum of 3 quarters · filed 2025-05-15 | $30.00M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $10.00M derived: sum of 2 quarters · filed 2025-03-31 | $20.00M derived: sum of 3 quarters · filed 2025-03-31 | $30.00M 10-K · filed 2025-03-31 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $10.00M derived: sum of 2 quarters · filed 2024-11-14 | $20.00M 10-Q · filed 2024-11-14 | $30.00M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $20.00M 10-Q · filed 2024-08-13 | $30.00M derived: sum of 3 quarters · filed 2024-08-13 | $30.00M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $10.00M 10-Q · filed 2024-05-15 | $20.00M derived: sum of 2 quarters · filed 2024-05-15 | $20.00M derived: sum of 3 quarters · filed 2024-05-15 | $20.00M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $10.00M derived: sum of 2 quarters · filed 2024-03-29 | $10.00M derived: sum of 3 quarters · filed 2024-03-29 | $10.00M 10-K · filed 2024-03-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |